{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Multiple Sclerosis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 38,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 38,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01377870"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER_GOV"
                        ],
                        "OrgFullName": [
                              "Royan Institute"
                        ],
                        "OrgStudyId": [
                              "Royn-nerve-001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03778333"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Karolinska Institutet"
                        ],
                        "OrgStudyId": [
                              "MSC-progressive MS"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "35 Years"
                        ],
                        "NCTId": [
                              "NCT00781872"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS)"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Hadassah Medical Organization"
                        ],
                        "OrgStudyId": [
                              "MS22MSC-HMO-CTIL"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01854957"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "University of Genova"
                        ],
                        "OrgStudyId": [
                              "MESEMS"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01730547"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Karolinska Institutet"
                        ],
                        "OrgStudyId": [
                              "MSC-MS"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01895439"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "University of Jordan"
                        ],
                        "OrgStudyId": [
                              "MSUJCTC"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 7,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01228266"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Hospital Clinic of Barcelona"
                        ],
                        "OrgStudyId": [
                              "CMM-EM"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 8,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01364246"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Shenzhen Beike Bio-Technology Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "BKCR-MS-1.0(2010)"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 9,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02403947"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "University Hospital, Toulouse"
                        ],
                        "OrgStudyId": [
                              "12 394 03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 10,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02034188"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Translational Biosciences"
                        ],
                        "OrgStudyId": [
                              "TBS-UCMSC-001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 11,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04823000"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Long Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cells (MSC) Injections in Patients With Progressive Forms of Multiple Sclerosis (MS)"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Hadassah Medical Organization"
                        ],
                        "OrgStudyId": [
                              "MSC-MS-001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 12,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00395200"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "University of Cambridge"
                        ],
                        "OrgStudyId": [
                              "MRCRG44871"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 13,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02035514"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Germans Trias i Pujol Hospital"
                        ],
                        "OrgStudyId": [
                              "CELLTRiMS"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 14,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01056471"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Andalusian Network for Design and Translation of Advanced Therapies"
                        ],
                        "OrgStudyId": [
                              "CMM/EM/2008"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 15,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01606215"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Stem Cells in Rapidly Evolving Active Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Imperial College London"
                        ],
                        "OrgStudyId": [
                              "CRO1959"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 16,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04749667"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Haukeland University Hospital"
                        ],
                        "OrgStudyId": [
                              "159326"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 17,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01933802"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Tisch Multiple Sclerosis Research Center of New York"
                        ],
                        "OrgStudyId": [
                              "TISCHMS-MSCNP-001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 18,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03355365"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Tisch Multiple Sclerosis Research Center of New York"
                        ],
                        "OrgStudyId": [
                              "TISCHMS-MSCNP-002"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 19,
                        "MaximumAge": [],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT05003388"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "The Foundation for Orthopaedics and Regenerative Medicine"
                        ],
                        "OrgStudyId": [
                              "SC-8-ATG-9-03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 20,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT05532943"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Ever Supreme Bio Technology Co., Ltd."
                        ],
                        "OrgStudyId": [
                              "ES-CMSC01-D1101"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 21,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02326935"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "American CryoStem Corporation"
                        ],
                        "OrgStudyId": [
                              "CRYO-MS-ADSC-006"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 22,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03326505"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study."
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "University of Jordan"
                        ],
                        "OrgStudyId": [
                              "ALLOMSUJCTC"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 23,
                        "MaximumAge": [
                              "55 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00813969"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "The Cleveland Clinic"
                        ],
                        "OrgStudyId": [
                              "MS-MSC-001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 24,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02239393"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "MEsenchymal Stem Cell Therapy for CAnadian MS Patients"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Ottawa Hospital Research Institute"
                        ],
                        "OrgStudyId": [
                              "20140368"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 25,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03822858"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Tisch Multiple Sclerosis Research Center of New York"
                        ],
                        "OrgStudyId": [
                              "TISCHMS-MSCNP-003"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 26,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02587715"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Novo Cellular Medicine Institute LLP"
                        ],
                        "OrgStudyId": [
                              "PRT/NOVO/2015/001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 27,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02418325"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Genesis Limited"
                        ],
                        "OrgStudyId": [
                              "PRT/GENESIS/2015/001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 28,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02166021"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Hadassah Medical Organization"
                        ],
                        "OrgStudyId": [
                              "MSC-MS-001-IL"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 29,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT05116540"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Hope Biosciences"
                        ],
                        "OrgStudyId": [
                              "HBMS01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 30,
                        "MaximumAge": [
                              "50 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01745783"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Andalusian Network for Design and Translation of Advanced Therapies"
                        ],
                        "OrgStudyId": [
                              "CeTMMo/EM/2010"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 31,
                        "MaximumAge": [
                              "60 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02495766"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Banc de Sang i Teixits"
                        ],
                        "OrgStudyId": [
                              "XCEL-MS-02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 32,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04956744"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Single Dose of IV IMS001 in Subjects With Multiple Sclerosis and Treatment Failure to Prior Disease Modifying Treatments (DMTs)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "ImStem Biotechnology"
                        ],
                        "OrgStudyId": [
                              "IMS001-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 33,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03799718"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn\u00ae [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Brainstorm-Cell Therapeutics"
                        ],
                        "OrgStudyId": [
                              "BCT-101-US"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 34,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "20 Years"
                        ],
                        "NCTId": [
                              "NCT03069170"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis."
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Stem Cells Arabia"
                        ],
                        "OrgStudyId": [
                              "SCA-MS1"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 35,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02249676"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Tianjin Medical University General Hospital"
                        ],
                        "OrgStudyId": [
                              "IRB2013-055-02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 36,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04821479"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Safety and Clinical Effects of Repeated Intrathecal Injections of Autologous Mesenchymal Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Hadassah Medical Organization"
                        ],
                        "OrgStudyId": [
                              "0208-16-HMO"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 37,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04520373"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "CELLTOP Part II: A Phase II Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Mayo Clinic"
                        ],
                        "OrgStudyId": [
                              "19-011706"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 38,
                        "MaximumAge": [
                              "65 Years"
                        ],
                        "MinimumAge": [
                              "15 Years"
                        ],
                        "NCTId": [
                              "NCT00962923"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
                        ],
                        "OrgStudyId": [
                              "NJGLYY003"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}